Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
- PMID: 3798106
- DOI: 10.1126/science.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Abstract
The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Similar articles
-
neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.J Clin Oncol. 1998 Apr;16(4):1340-9. doi: 10.1200/JCO.1998.16.4.1340. J Clin Oncol. 1998. PMID: 9552035
-
The association of HER-2/neu amplification with breast cancer recurrence.Arch Surg. 2000 Dec;135(12):1469-74. doi: 10.1001/archsurg.135.12.1469. Arch Surg. 2000. PMID: 11115354
-
HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.Anticancer Res. 1992 Mar-Apr;12(2):419-25. Anticancer Res. 1992. PMID: 1349794
-
Follow-up study of HER-2/neu amplification in primary breast cancer.Cancer Res. 1991 Feb 1;51(3):944-8. Cancer Res. 1991. PMID: 1988136 Review.
-
The significance of oncogene amplification in primary breast cancer.Int J Cancer. 1989 Feb 15;43(2):270-2. doi: 10.1002/ijc.2910430218. Int J Cancer. 1989. PMID: 2563720 Review.
Cited by
-
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population.Oncol Ther. 2024 Jun 5. doi: 10.1007/s40487-024-00284-5. Online ahead of print. Oncol Ther. 2024. PMID: 38836997
-
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.Nat Med. 2024 Jun 2. doi: 10.1038/s41591-024-03021-7. Online ahead of print. Nat Med. 2024. PMID: 38825627
-
Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.Breast Cancer (Dove Med Press). 2024 May 25;16:253-268. doi: 10.2147/BCTT.S457845. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 38812479 Free PMC article.
-
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07367-x. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38797792
-
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.Biomedicines. 2024 May 14;12(5):1088. doi: 10.3390/biomedicines12051088. Biomedicines. 2024. PMID: 38791050 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous